Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Grötsch H[au]:

Search results

Items: 41

1.

Structural Basis for the Activation of the Deubiquitinase Calypso by the Polycomb Protein ASX.

De I, Chittock EC, Grötsch H, Miller TCR, McCarthy AA, Müller CW.

Structure. 2019 Mar 5;27(3):528-536.e4. doi: 10.1016/j.str.2018.11.013. Epub 2019 Jan 10.

PMID:
30639226
2.

ORP-Mediated ER Contact with Endocytic Sites Facilitates Actin Polymerization.

Encinar Del Dedo J, Idrissi FZ, Fernandez-Golbano IM, Garcia P, Rebollo E, Krzyzanowski MK, Grötsch H, Geli MI.

Dev Cell. 2017 Dec 4;43(5):588-602.e6. doi: 10.1016/j.devcel.2017.10.031. Epub 2017 Nov 22.

3.

A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT.

Miller TC, Simon B, Rybin V, Grötsch H, Curtet S, Khochbin S, Carlomagno T, Müller CW.

Nat Commun. 2016 Dec 19;7:13855. doi: 10.1038/ncomms13855.

4.

Crosstalk between PI(4,5)P₂and CK2 modulates actin polymerization during endocytic uptake.

Fernández-Golbano IM, Idrissi FZ, Giblin JP, Grosshans BL, Robles V, Grötsch H, Borrás Mdel M, Geli MI.

Dev Cell. 2014 Sep 29;30(6):746-58. doi: 10.1016/j.devcel.2014.07.020.

5.

Structural and functional characterization of a phosphatase domain within yeast general transcription factor IIIC.

Taylor NM, Glatt S, Hennrich ML, von Scheven G, Grötsch H, Fernández-Tornero C, Rybin V, Gavin AC, Kolb P, Müller CW.

J Biol Chem. 2013 May 24;288(21):15110-20. doi: 10.1074/jbc.M112.427856. Epub 2013 Apr 8.

6.

RWDD1 interacts with the ligand binding domain of the androgen receptor and acts as a coactivator of androgen-dependent transactivation.

Grötsch H, Kunert M, Mooslehner KA, Gao Z, Struve D, Hughes IA, Hiort O, Werner R.

Mol Cell Endocrinol. 2012 Jul 6;358(1):53-62. doi: 10.1016/j.mce.2012.02.020. Epub 2012 Mar 2.

PMID:
22406838
7.

Calmodulin dissociation regulates Myo5 recruitment and function at endocytic sites.

Grötsch H, Giblin JP, Idrissi FZ, Fernández-Golbano IM, Collette JR, Newpher TM, Robles V, Lemmon SK, Geli MI.

EMBO J. 2010 Sep 1;29(17):2899-914. doi: 10.1038/emboj.2010.159. Epub 2010 Jul 20.

8.

46,XY disorders of sex development--the undermasculinised male with disorders of androgen action.

Werner R, Grötsch H, Hiort O.

Best Pract Res Clin Endocrinol Metab. 2010 Apr;24(2):263-77. doi: 10.1016/j.beem.2009.11.002. Review.

PMID:
20541151
9.

Distinct acto/myosin-I structures associate with endocytic profiles at the plasma membrane.

Idrissi FZ, Grötsch H, Fernández-Golbano IM, Presciatto-Baschong C, Riezman H, Geli MI.

J Cell Biol. 2008 Mar 24;180(6):1219-32. doi: 10.1083/jcb.200708060. Epub 2008 Mar 17.

10.

TEDS site phosphorylation of the yeast myosins I is required for ligand-induced but not for constitutive endocytosis of the G protein-coupled receptor Ste2p.

Grosshans BL, Grötsch H, Mukhopadhyay D, Fernández IM, Pfannstiel J, Idrissi FZ, Lechner J, Riezman H, Geli MI.

J Biol Chem. 2006 Apr 21;281(16):11104-14. Epub 2006 Feb 13.

11.

Real-time detection of hyperosmotic stress response in optically trapped single yeast cells using Raman microspectroscopy.

Singh GP, Creely CM, Volpe G, Grötsch H, Petrov D.

Anal Chem. 2005 Apr 15;77(8):2564-8.

PMID:
15828794
12.

Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats.

Hropot M, Langer KH, Wiemer G, Grötsch H, Linz W.

Naunyn Schmiedebergs Arch Pharmacol. 2003 Mar;367(3):312-7. Epub 2003 Jan 25.

PMID:
12644905
13.

Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency.

Hropot M, Grötsch H, Klaus E, Langer KH, Linz W, Wiemer G, Schölkens BA.

Naunyn Schmiedebergs Arch Pharmacol. 1994 Dec;350(6):646-52.

PMID:
7535899
14.

Sorbitol-accumulating pyrimidine derivatives.

Geisen K, Utz R, Grötsch H, Lang HJ, Nimmesgern H.

Arzneimittelforschung. 1994 Sep;44(9):1032-43.

PMID:
7986240
15.

Interference in clinical laboratory tests, with special regard to the bilirubin assay: effects of a metabolite of the new prolyl 4-hydroxylase inhibitor, Lufironil.

Baader E, Bickel M, Damm D, Donaubauer HH, Fehlhaber HW, Grötsch H, Günzler V, Teetz V, Volz M.

Eur J Clin Chem Clin Biochem. 1994 Jul;32(7):515-20.

PMID:
7981331
16.

Recombinant hirudin, a new anticoagulant, has no effect on faecal blood loss.

Meyer BH, Luus HG, Muller FO, Badenhorst PN, Lotter MG, Röthig HJ, Grötsch H, Rosenkranz B.

Br J Clin Pharmacol. 1992 May;33(5):524-6.

17.

Pharmacokinetic investigations of the alpha-human thrombin-hirudin complex in rhesus monkeys.

Grötsch H, Hropot M, Berscheid G, Crause P, Malerczyk V, Apidopoulos G, Haun G, Husák B.

Thromb Res. 1992 May 1;66(2-3):271-5. No abstract available.

PMID:
1412198
18.
19.

Degradation of rDNA hirudin and alpha-human thrombin hirudin complex in liver and kidney homogenates from rat.

Grötsch H, Hropot M.

Thromb Res. 1991 Dec 15;64(6):763-7. No abstract available.

PMID:
1798966
20.

Influence of seasonal biorhythms on urinary excretion of enzymes and other parameters.

Grötsch H, Hropot M, Klaus E, Wesely J.

J Clin Chem Clin Biochem. 1990 May;28(5):285-6.

PMID:
2380664
21.

Absence of interaction between ramipril, a new ACE-inhibitor, and phenprocoumon, an anticoagulant agent.

Verho M, Malerczyk V, Grötsch H, Zenbil I.

Pharmatherapeutica. 1989;5(6):392-9.

PMID:
2531901
22.

Pharmacodynamic effects of a single 10-mg dose of the angiotensin converting enzyme inhibitor ramipril in patients with impaired renal function.

Ocón-Pujadas J, Debusmann ER, Jane F, Lahn W, Irmisch R, Mora J, Grötsch H.

J Cardiovasc Pharmacol. 1989;13 Suppl 3:S45-8.

PMID:
2474101
23.

Recommendation for the measurement of "alanine aminopeptidase" in urine.

Mattenheimer H, Frölke W, Grötsch H, Maruhn D, Simane Z.

J Clin Chem Clin Biochem. 1988 Oct;26(10):635-44.

PMID:
2906650
24.
25.

Renal tolerance of cefpirome (HR 810), a new cephalosporin antibiotic.

Verho M, Maass L, Malerczyk V, Grötsch H.

Infection. 1987 May-Jun;15(3):215-9.

PMID:
2886437
27.

Absence of interaction between ofloxacin and phenprocoumon.

Verho M, Malerczyk V, Rosenkranz B, Grötsch H.

Curr Med Res Opin. 1987;10(7):474-9.

PMID:
3476252
28.

Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.

Dagrosa EE, Hajdú P, Malerczyk V, de Looze S, Seeger K, Grötsch H.

Clin Ther. 1987;10(1):18-31. Erratum in: Clin Ther 1988;10(4):466.

PMID:
3450392
29.

The excretion of renal enzymes during rest and exercise: a double-blind comparison between placebo and penbutolol.

Verho M, Färber G, Heinen B, Grötsch H.

Int J Clin Pharmacol Res. 1987;7(1):27-32.

PMID:
2884191
30.

Identification of inhibitors of urinary alanine aminopeptidase.

Mattenheimer H, Frölke W, Grötsch H, Simane Z.

Clin Chim Acta. 1986 Oct 31;160(2):129-35.

PMID:
2877757
31.

Enzymuria in streptozotocin-diabetic rats.

Grötsch H, Hropot M, Kief H, Klaus E.

J Clin Chem Clin Biochem. 1986 Aug;24(8):533-9.

PMID:
3531386
32.

Enzymuria of the rat: biorhythms and sex differences.

Grötsch H, Hropot M, Klaus E, Malerczyk V, Mattenheimer H.

J Clin Chem Clin Biochem. 1985 Jun;23(6):343-7.

PMID:
2862218
33.

Renal tolerance of ofloxacin, a new gyrase inhibitor.

Verho M, Dagrosa EE, Usinger P, Grötsch H, Malerczyk V, Uchida M, Rangoonwala R.

Pharmatherapeutica. 1985;4(5):306-13.

PMID:
2866542
34.

Enzymuria of the rat: the preparation of urine for enzyme analysis.

Berscheid G, Grötsch H, Hropot M, Klaus E, Mattenheimer H.

J Clin Chem Clin Biochem. 1983 Dec;21(12):799-804.

PMID:
6141212
35.

Effect on salivary enzymes of alpha-amylase inhibitor HOE 467.

Rupp W, Grigoleit HG, Grötsch H.

Lancet. 1983 May 14;1(8333):1103-4. No abstract available.

PMID:
6188934
36.

Tobramycin nephrotoxicity: failure of cefotaxime to potentiate renal toxicity.

Kuhlmann J, Seidel G, Grötsch H.

Infection. 1982;10(4):233-9.

PMID:
6127319
37.

Exercise induced changes of catecholamines and potassium in plasma of dogs after treatment with propranolol.

Staib AH, Appel E, Starey F, Lindner E, Grötsch H, Palm D, Grobecker H.

Arzneimittelforschung. 1980;30(9):1514-7.

PMID:
7193019
38.

The value of urinary enzyme diagnosis in urinary bladder carcinoma. Experimental and clinical research data.

Harzmann R, Heller W, Bichler KH, Gericke D, Grötsch H, Schmidt K.

Curr Probl Clin Biochem. 1979;(9):113-21. No abstract available.

PMID:
446068
39.

Carcinogen control in the urine of dogs during bladder carcinogenesis.

Gericke D, Grötsch H, Harzmann R, Bichler KH.

Naturwissenschaften. 1977 Jul;64(7):392-3. No abstract available.

PMID:
927546
40.

[A method for the gradual determination of hypoxic damage in the Langendorff isolated guinea pig heart].

Lindner E, Grötsch H.

Arzneimittelforschung. 1973 Jul;23(7):926-9. German. No abstract available.

PMID:
4800447

Supplemental Content

Loading ...
Support Center